Healthcare provider profile · identity verified

Sena Rae St John, D.O.

Internal Medicine · IONIA, MI · NPI 1437443033

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	566	226
Losartan Potassium	Losartan Potassium	226	95
Amlodipine Besylate	Amlodipine Besylate	210	96
Levothyroxine Sodium	Levothyroxine Sodium	200	79
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	198	64
Lisinopril	Lisinopril	186	81
Omeprazole	Omeprazole	162	74
Gabapentin	Gabapentin	147	65
Rosuvastatin Calcium	Rosuvastatin Calcium	139	67
Atenolol	Atenolol	135	52
Potassium Chloride	Potassium Chloride	134	57
Metformin Hcl	Metformin Hcl	128	59
Glipizide	Glipizide	108	49
Metformin Hcl Er	Metformin Hcl	103	49
Furosemide	Furosemide	99	41
Meloxicam	Meloxicam	99	45
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	93	37
Simvastatin	Simvastatin	89	35
Ozempic	Semaglutide	87	21
Albuterol Sulfate Hfa	Albuterol Sulfate	83	54
Pantoprazole Sodium	Pantoprazole Sodium	83	40
Trazodone Hcl	Trazodone Hcl	83	35
Hydrochlorothiazide	Hydrochlorothiazide	81	35
Metoprolol Tartrate	Metoprolol Tartrate	75	37
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	73	27
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	72	30
Alendronate Sodium	Alendronate Sodium	71	34
Duloxetine Hcl	Duloxetine Hcl	66	28
Ibuprofen	Ibuprofen	66	34
Tamsulosin Hcl	Tamsulosin Hcl	55	23
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	52	19
Sertraline Hcl	Sertraline Hcl	51	18
Azelastine Hcl	Azelastine Hcl	50	20
Pradaxa	Dabigatran Etexilate Mesylate	50	20
Tramadol Hcl	Tramadol Hcl	50	19
Baclofen	Baclofen	47	16
Famotidine	Famotidine	42	24
Ondansetron Odt	Ondansetron	41	11
Hydralazine Hcl	Hydralazine Hcl	40	15
Jardiance	Empagliflozin	39	18
Estradiol	Estradiol	38	22
Spironolactone	Spironolactone	38	14
Triamcinolone Acetonide	Triamcinolone Acetonide	38	25
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	37	11
Allopurinol	Allopurinol	36	18
Bisoprolol Fumarate	Bisoprolol Fumarate	35	16
Clopidogrel	Clopidogrel Bisulfate	34	19
Wixela Inhub	Fluticasone Propion/Salmeterol	34	18
Terazosin Hcl	Terazosin Hcl	33	18
Finasteride	Finasteride	32	17
Humulin N	Insulin Nph Human Isophane	32	15
Lidocaine	Lidocaine	32	11
Metronidazole	Metronidazole	31	12
Oxybutynin Chloride Er	Oxybutynin Chloride	31	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	31	11
Spiriva Respimat	Tiotropium Bromide	28	12
Prednisone	Prednisone	27	13
Breyna	Budesonide/Formoterol Fumarate	24	18
Eliquis	Apixaban	24	11
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	12
Mupirocin	Mupirocin	22	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	12
Carvedilol	Carvedilol	21	suppressed
Colchicine	Colchicine	21	11
Escitalopram Oxalate	Escitalopram Oxalate	21	suppressed
Naproxen	Naproxen	21	11
Buspirone Hcl	Buspirone Hcl	20	suppressed
Hydrocortisone	Hydrocortisone	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Methocarbamol	Methocarbamol	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	19	19
Donepezil Hcl	Donepezil Hcl	18	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	18	suppressed
Montelukast Sodium	Montelukast Sodium	18	suppressed
Morphine Sulfate Er	Morphine Sulfate	18	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	18	suppressed
Xifaxan	Rifaximin	18	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	17	17
Chlorthalidone	Chlorthalidone	17	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Nystatin	Nystatin	16	suppressed
Temazepam	Temazepam	16	suppressed
Terbinafine Hcl	Terbinafine Hcl	16	suppressed
Humulin R	Insulin Regular, Human	15	suppressed
Lactulose	Lactulose	15	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Pravastatin Sodium	Pravastatin Sodium	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	15	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Midodrine Hcl	Midodrine Hcl	14	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	14	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	14	suppressed
Alvesco	Ciclesonide	13	12
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	12
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Trospium Chloride	Trospium Chloride	13	suppressed
Victoza 2-Pak	Liraglutide	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Rizatriptan	Rizatriptan Benzoate	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Fluconazole	Fluconazole	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Nabumetone	Nabumetone	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error